18^th European Biosimilars Congress

Biosimilars & Biologics: Clinical Studies & Trials

This track includes Clinical Studies & Trials on major diseases Risk management, and quality affairs, Case studies, and clinical models, Transgenic animals, Targeted cell line development, Toxicological studies and Aspects of genotoxicity tests. Clinical trials are designed in stages I-IV so as to receive a clear picture of the drug candidate in respect to its pharmacokinetics and pharmacodynamics parameters. Research estimates that there are 280 Biosimilars in the pipeline, and clinical trials are increasing by 20% per year. Biologics also represent over 40 percent of the drugs in each of the preclinical, Phase I, Phase II, and Phase III trial stages.